Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Top Cited Papers
Open Access
- 1 January 2010
- Vol. 140 (2), 209-221
- https://doi.org/10.1016/j.cell.2009.12.040
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- A dimerization-dependent mechanism drives RAF catalytic activationNature, 2009
- Inhibitors paradoxically prime kinasesNature Chemical Biology, 2009
- Inhibitor hijacking of Akt activationNature Chemical Biology, 2009
- PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activityNature Structural & Molecular Biology, 2009
- Randomized Phase II Trial Evaluating Two Paclitaxel and Cisplatin–Containing Chemoradiation Regimens As Adjuvant Therapy in Resected Gastric Cancer (RTOG-0114)Journal of Clinical Oncology, 2009
- BrafV600E cooperates with Pten loss to induce metastatic melanomaNature Genetics, 2009
- Therapeutic strategies for inhibiting oncogenic BRAF signalingCurrent Opinion in Pharmacology, 2008
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in MelanomaCancer Research, 2008
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProceedings of the National Academy of Sciences, 2008
- The structural basis for substrate recognition and control by protein kinases1FEBS Letters, 1998